Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC).

被引：0
|
作者：
Choueiri, Toni K.
Albiges, Laurence
Fan, Li
Perini, Rodolfo F.
Zojwalla, Naseem J.
Powles, Thomas
Rini, Brian, I
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Gustave Roussy, Villejuif, France
[3] Merck & Co Inc, Kenilworth, NJ USA
[4] Peloton Therapeut Inc, Dallas, TX USA
[5] Barts Canc Inst, London, England
[6] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5094
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of the oral hypoxia-inducible factor 2α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Tykodi, Scott S.
    Bauer, Todd Michael
    McDermott, David F.
    Arrowsmith, Edward
    Zojwalla, Naseem J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Phase 2 study of the oral hypoxia-inducible factor 2[alpha] (HIF-2[alpha]) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
    Choueiri, Toni K.
    Bauer, Todd Michael
    McDermott, David F.
    Arrowsmith, Edward
    Roy, Ananya
    Perini, Rodolfo F.
    Vickery, Donna
    Tykodi, Scott S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)
    McDermott, D. F.
    Choueiri, T. K.
    Bauer, T. M.
    Arrowsmith, E.
    Roy, A.
    Perini, R.
    Vickery, D.
    Tykodi, S. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S681 - S681
  • [4] MK-6482, a hypoxia-inducible factor 2[alpha] inhibitor (HIF-2[alpha]), versus everolimus in heavily pretreated, immune checkpoint-inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study.
    Choueiri, Toni K.
    Albiges, Laurence
    Fan, Li
    Perini, Rodolfo F.
    Vickery, Donna
    Powles, Thomas
    Rini, Brian, I
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [5] Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
    Srinivasan, Ramaprasad
    Donskov, Frede
    Iliopoulos, Othon
    Rathmell, Wendy Kimryn
    Narayan, Vivek
    Maughan, Benjamin L.
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Welsh, Sarah Joanne
    Roy, Ananya
    Liu, Yanfang
    Perini, Rodolfo F.
    Linehan, W. Marston
    Jonasch, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC)
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Bauer, Todd Michael
    Merchan, Jaime R.
    Papadopoulos, Kyriakos P.
    McDermott, David F.
    Michaelson, M. Dror
    Appleman, Leonard Joseph
    Thamake, Sanjay
    Zojwalla, Naseem J.
    Jonasch, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Phase II study of the oral hypoxia-inducible factor 2[alpha] (HIF-2[alpha]) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
    Iliopoulos, Othon
    Jonasch, Eric
    Donskov, Frede
    Narayan, Vivek
    Maughan, Benjamin Louis
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Welsh, Sarah J.
    Thamake, Sanjay
    Perini, Rodolfo F.
    Park, Eric Kristopher
    Linehan, Marston W.
    Srinivasan, Ramaprasad
    Rathmell, Kimryn W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] The oral HIF-2 [alpha] inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study.
    Bauer, Todd Michael
    Choueiri, Toni K.
    Papadopoulos, Kyriakos P.
    Plimack, Elizabeth R.
    Merchan, Jaime R.
    McDermott, David F.
    Michaelson, Dror M.
    Appleman, Leonard Joseph
    Thamake, Sanjay
    Perini, Rodolfo F.
    Park, Eric Kristopher
    Jonasch, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [9] Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.
    Jonasch, Eric
    Donskov, Frede
    Iliopoulos, Othon
    Rathmell, Wendy Kimryn
    Narayan, Vivek
    Maughan, Benjamin Louis
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Welsh, Sarah J.
    Thamake, Sanjay
    Park, Eric Kristopher
    Zojwalla, Naseem J.
    Perini, Rodolfo F.
    Linehan, W. Marston
    Srinivasan, Ramaprasad
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma.
    Doshi, Sahil D.
    Kuo, Fengshen
    Knezevic, Andrea
    Kotecha, Ritesh R.
    Motzer, Robert J.
    Hakimi, A. Ari
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 445 - 445
12345